1027306-05-3

Upstream product

• 609846-33-5 (S)-[2-(N'-tert-butoxycarbonyl-hydrazino)-ethoxy]-succinic acid dimethyl ester 
• 609846-34-6 [(S)-4-amino-3-oxo-morpholin-2-yl]-acetic acid methyl ester 
• 441764-54-1 (S)-2-(2-oxo-ethoxy)-succinic acid dimethyl ester 
• 609846-56-2 [(S)-4-(4-chloro-2,5-dimethyl-benzenesulfonylamino)-3-oxo-morpholin-2-yl]-acetic acid methyl ester 

Downstream Products

• 609846-96-0 N-(4-benzyloxycarbonylamidino-benzyl)-2-[(S)-4-(4-chloro-2,5-dimethyl-benzenesulfonylamino)-3-oxo-morpholin-2-yl]-acetamide acid benzyl ester 

Relevant academic research and scientific papers

Synthesis and SAR of thrombin inhibitors incorporating a novel 4-amino-morpholinone scaffold: Analysis of X-ray crystal structure of enzyme inhibitor complex

A 4-amino-2-carboxymethyl-3-morpholinone structural motif derived from malic acid has been used to mimic D-Phe-Pro in the thrombin inhibiting tripeptide D-Phe-Pro-Arg. The arginine in D-Phe-Pro-Arg was replaced by the more rigid P1 truncated p-amidinobenzylamine (Pab). These new thrombin inhibitors were used to probe the inhibitor binding site of α-thrombin. The best candidate in this series of thrombin inhibitors exhibits an in vitro IC50 of 0.130 μM. Interestingly, the stereochemistry of the 4-amino-2-carboxymethyl-3-morpholinone motif is reversed for the most active compounds compared to that of a previously reported 2-carboxymethyl-3-morpholinone series. The X-ray crystal structure of the lead inhibitor cocrystallized with α-thrombin is discussed.